Literature DB >> 12222713

Homocysteine and other vascular risk factors in patients with phenylketonuria on a diet.

K H Schulpis1, G A Karikas, E Papakonstantinou.   

Abstract

UNLABELLED: The aim of this study was to investigate the known risk factors, such as lipids, homocysteine and endothelin, for the development of coronary artery disease (CAD) in phenylketonuria (PKU) patients, depending on their diet. The PKU patients (n = 74) were divided into two groups. Group A (n = 34; mean age 6.78 +/- 1.5 y) adhered strictly to a diet and group B (n = 40; mean age 8.0 +/- 3.2 y) did not comply with the diet. The control group comprised 50 healthy non-PKU children. All groups were evaluated for blood levels of homocysteine and vitamin B6 by high-performance liquid chromatography, vitamin B12 and folate in serum by a radioassay, lipids by a routine method, and lipoprotein(a) and endothelin-1 with an immunoassay. Homocysteine levels (28.65 +/- 3.3 micromol l(-1)) were increased in group A compared with group B (6.86 +/- 1.6 micromol l(-1)) and the controls (6.9 +/- 2.0 micromol l(-1)) (p < 0.001). Vitamin B6 (10.7 +/- 10.9 nmol l(-1)), vitamin B12 (98.5 +/- 22.3 pmol l(-1)), folate (2.35 +/- 1.3 nmol l(-1)) and lipids were decreased in group A. The other vascular risk factors, which were not dependent on diet [lipoprotein(a) and endothelin-1], did not differ among the three groups.
CONCLUSION: PKU patients on a strict diet had low vitamin B6, vitamin B12 and folate levels resulting in moderate hyperhomocysteinaemia. The evaluation of these vitamins at short intervals and their supplementation could be an early measure in the prevention of CAD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222713     DOI: 10.1080/080352502760148612

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

Review 1.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

2.  Phenylketonuria: an inborn error of phenylalanine metabolism.

Authors:  Robin A Williams; Cyril D S Mamotte; John R Burnett
Journal:  Clin Biochem Rev       Date:  2008-02

Review 3.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

4.  High dietary folic Acid and high plasma folate in children and adults with phenylketonuria.

Authors:  Linn Helene Stølen; Rina Lilje; Jens Veilemand Jørgensen; Yngve Thomas Bliksrud; Runar Almaas
Journal:  JIMD Rep       Date:  2013-10-18

5.  Status of nutrients important in brain function in phenylketonuria: a systematic review and meta-analysis.

Authors:  Gina A Montoya Parra; Rani H Singh; Aysun Cetinyurek-Yavuz; Mirjam Kuhn; Anita MacDonald
Journal:  Orphanet J Rare Dis       Date:  2018-06-26       Impact factor: 4.123

Review 6.  Food Regime for Phenylketonuria: Presenting Complications and Possible Solutions.

Authors:  Sudipt Kumar Dalei; Nidhi Adlakha
Journal:  J Multidiscip Healthc       Date:  2022-01-18

7.  Lipid profile status and other related factors in patients with Hyperphenylalaninaemia.

Authors:  María L Couce; Isidro Vitoria; Luís Aldámiz-Echevarría; Ana Fernández-Marmiesse; Iria Roca; Marta Llarena; Paula Sánchez-Pintos; Rosaura Leis; Alvaro Hermida
Journal:  Orphanet J Rare Dis       Date:  2016-09-09       Impact factor: 4.123

8.  Arterial stiffness assessment in patients with phenylketonuria.

Authors:  Alvaro Hermida-Ameijeiras; Vanesa Crujeiras; Iria Roca; Carlos Calvo; Rosaura Leis; María-Luz Couce
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  The cardiovascular phenotype of adult patients with phenylketonuria.

Authors:  Aline Azabdaftari; Markus van der Giet; Mirjam Schuchardt; Julia B Hennermann; Ursula Plöckinger; Uwe Querfeld
Journal:  Orphanet J Rare Dis       Date:  2019-09-06       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.